Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

NRG GY025

Trial Overview

Official Title

A Randomized Phase II Trial of Nivolumab and Ipilimumab compared to Nivolumab Monotherapy in patients with deficient mismatch repair system recurrent endometrial carcinoma.

Study Purpose

To find out if combining two immunotherapy drugs, nivolumab and ipilimumab, is better or worse than the usual approach with a single immunotherapy agent.

Diagnosis

Endometrial cancer that has spread to other parts of the body and/or has not responded to previous treatment(s), and is mismatch repair deficient (dMMR)

Eligibility

Recurrent endometrial cancer, 1-2 prior lines of treatment.  No serous carcinoma or carcinosarcoma.

Intervention

Nivolumab+ Ipilimumab VS. Nivolumab

For more information, click the link below:

 

https://clinicaltrials.gov/study/NCT05112601?term=GY025&rank=1

 

Key Participation Requirements
Trial Location(s)
Methodist Estabrook Cancer Center Methodist Jennie Edmundson Hospital
Gender
Female
Age
19 Years and over
Enrollment Status
Recruiting
Phase
Phase II
Methodist Health System Trial Code
NRG GY025